120 related articles for article (PubMed ID: 24937026)
1. Complication of a 2-mg estradiol vaginal ring: fibrotic vaginal adhesion.
Pratts ME; Shen W
Menopause; 2014 Nov; 21(11):1254-6. PubMed ID: 24937026
[TBL] [Abstract][Full Text] [Related]
2. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
Crandall C
J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
[TBL] [Abstract][Full Text] [Related]
3. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring.
Smith P
Acta Obstet Gynecol Scand Suppl; 1993; 157():1-26. PubMed ID: 8393609
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery.
Karp DR; Jean-Michel M; Johnston Y; Suciu G; Aguilar VC; Davila GW
Female Pelvic Med Reconstr Surg; 2012; 18(4):211-5. PubMed ID: 22777369
[TBL] [Abstract][Full Text] [Related]
5. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
6. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy.
Henriksson L; Stjernquist M; Boquist L; Alander U; Selinus I
Am J Obstet Gynecol; 1994 Sep; 171(3):624-32. PubMed ID: 8092207
[TBL] [Abstract][Full Text] [Related]
7. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging.
Henriksson L; Stjernquist M; Boquist L; Cedergren I; Selinus I
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):85-92. PubMed ID: 8572039
[TBL] [Abstract][Full Text] [Related]
8. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study.
Chompootaweep S; Nunthapisud P; Trivijitsilp P; Sentrakul P; Dusitsin N
Clin Pharmacol Ther; 1998 Aug; 64(2):204-10. PubMed ID: 9728901
[TBL] [Abstract][Full Text] [Related]
9. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
[TBL] [Abstract][Full Text] [Related]
10. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
[TBL] [Abstract][Full Text] [Related]
11. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet.
Weisberg E; Ayton R; Darling G; Farrell E; Murkies A; O'Neill S; Kirkegard Y; Fraser IS
Climacteric; 2005 Mar; 8(1):83-92. PubMed ID: 15804736
[TBL] [Abstract][Full Text] [Related]
12. Recognizing and treating urogenital atrophy in postmenopausal women.
Goldstein I
J Womens Health (Larchmt); 2010 Mar; 19(3):425-32. PubMed ID: 20156082
[TBL] [Abstract][Full Text] [Related]
13. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review.
Sarkar NN
Eur J Contracept Reprod Health Care; 2003 Dec; 8(4):217-24. PubMed ID: 15006269
[TBL] [Abstract][Full Text] [Related]
14. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets.
Panay N; Maamari R
Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176
[TBL] [Abstract][Full Text] [Related]
15. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
Dugal R; Hesla K; Sørdal T; Aase KH; Lilleeidet O; Wickstrøm E
Acta Obstet Gynecol Scand; 2000 Apr; 79(4):293-7. PubMed ID: 10746845
[TBL] [Abstract][Full Text] [Related]
16. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.
Simon JA; Maamari RV
Climacteric; 2013 Aug; 16 Suppl 1():37-43. PubMed ID: 23848490
[TBL] [Abstract][Full Text] [Related]
17. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms.
Ben-Chetrit A; Hochner-Celnikier D; Lindenberg T; Zacut D; Shimonovitz S; Gelber H; Spitz IM
Isr Med Assoc J; 2005 May; 7(5):302-6. PubMed ID: 15909462
[TBL] [Abstract][Full Text] [Related]
18. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study.
Jonasson AF; Edwall L; Uvnäs-Moberg K
Menopause Int; 2011 Dec; 17(4):120-5. PubMed ID: 22120944
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women.
Eriksen B
Am J Obstet Gynecol; 1999 May; 180(5):1072-9. PubMed ID: 10329858
[TBL] [Abstract][Full Text] [Related]
20. [Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel].
Elkik F; Basdevant A; Corvol P
Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1737-9. PubMed ID: 3938250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
